<DOC>
	<DOCNO>NCT01163643</DOCNO>
	<brief_summary>The objective study identify concentration daily dose frequency BOL-303242-X ophthalmic suspension treat dry eye syndrome 12 week dose period .</brief_summary>
	<brief_title>Study Assess Safety Efficacy BOL-303242-X Ophthalmic Suspension Dry Eye Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Subjects diagnosis dry eye disease . Intraocular pressure ( IOP ) â‰¤28 mmHg IOP lowering medication . Subjects willing able refrain use contact lens study . Subjects know hypersensitivity contraindication component study medication . Subjects expect require concurrent treatment ophthalmic medication ( prescription counter ) . Subjects expect require treatment corticosteroid study . Subjects use topical systemic isotretinoin , cyclosporine , retinoid therapy within 30 day prior screen visit . Subjects undergone type ocular surgery within three month prior screen . Lacrimal punctal occlusion ( plugs cautery ) within 2 month Screening Visit . Subjects history presence chronic generalize systemic ocular disease Investigator feel might increase risk subject confound result study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>